Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2018-05-15 Earnings Release
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing financial results for the first quarter ended March 31, 2018, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length is 2905 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results.
2018-05-15 English
FORM 10-Q
Interim / Quarterly Report Q1 2018
2018-05-14 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is identified as a Schedule 14A filing, specifically a Definitive Additional Materials filing related to a proxy statement under the Securities Exchange Act of 1934. The presence of 'DEFA14A' and references to proxy materials indicate this is related to shareholder voting and solicitation information. The document length is short (2186 characters), and it does not contain detailed financial data or management discussion but rather proxy solicitation materials. Therefore, it fits the category of Remuneration Information (DEF 14A), which covers reports detailing compensation and proxy materials for shareholder votes.
2018-04-30 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2018-04-30 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes detailed information about the upcoming Annual Meeting of Stockholders, including proposals to be voted on such as election of directors, ratification of auditors, amendments to incentive plans, and amendments to the certificate of incorporation. It also contains instructions on voting, corporate governance details, executive compensation, and other related information typically found in proxy statements. The document is not the Annual Report itself, nor is it a voting results announcement or a report publication announcement. It is a solicitation of proxies and information statement for the Annual Meeting. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is a full proxy statement, not a brief notice or announcement.
2018-04-20 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and states that a press release announcing financial results for the fourth quarter and full year ended December 31, 2017, is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references an attached press release. The length of the document is 2977 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial report itself. It is not an Earnings Release (ER) because the actual press release is an exhibit, and the 8-K is the filing form. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-03-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.